Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 4829 (109th)

Reducing Fraudulent and Imitation Drugs Act of 2006

referredUnited States· United States Congress· EN

Introduced

1 March 2006

Last action

17 March 2006 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Burton, Dan [R-IN-5], Rep. Gutknecht, Gil [R-MN-1], Sen. Sanders, Bernard [I-VT], Rep. Emanuel, Rahm [D-IL-5], Rep. Herseth Sandlin, Stephanie [D-SD-At Large], Rep. Northup, Anne M. [R-KY-3], Rep. Jones, Walter B., Jr. [R-NC-3], Rep. DeFazio, Peter A. [D-OR-4], Rep. Souder, Mark E. [R-IN-3], Rep. DeLauro, Rosa L. [D-CT-3], Rep. Wamp, Zach [R-TN-3], Rep. English, Phil [R-PA-3], Rep. Shays, Christopher [R-CT-4]

Subjects

Healthcare

Source updated

15 August 2025

Healthcare

Summary

Reducing Fraudulent and Imitation Drugs Act of 2006 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible. Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses. Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: (1) overt optically variable counterfeit-resistant technologies into packaging; and (2) required prescription drug packaging technologies into multiple elements of the physical packaging of the drugs. Requires prescription drug shipments to include a label on the shipping container that incorporates packaging technologies. Deems a prescription drug to be misbranded if the packaging or labeling of the drug is in violation of a requirement or prohibition of this Act. Requires the Secretary to publish the National Specified List of Susceptible Prescription Drugs, consisting of not less than 30 of the most frequently counterfeited prescription drugs in the United States.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 1 March 2006

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 1 March 2006

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 1 March 2006

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 17 March 2006

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 1 March 2006

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 1 March 2006

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 1 March 2006

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.